Wainua (Eplontersen) Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Wainua contains eplontersen, a transthyretin (TTR)-directed antisense oligonucleotide. Its labelling describes it for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults, at the dose and schedule set by the prescriber.
Product Information
The following description reflects information associated with eplontersen and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults
- Described as reducing the amount of transthyretin (TTR) protein the body produces, which is described as reducing the build-up of amyloid deposits associated with the nerve damage in this disease
Described Dosage & Administration
- Given as a subcutaneous injection by a doctor or nurse, on the schedule set by the treating specialist
- Doses should be given on the schedule advised and not missed, to maintain the intended effect
- Its labelling describes supplementation with the recommended daily allowance of vitamin A during treatment
Described Side Effects
Commonly described side effects include:
- Injection-site reactions
- Reduced blood levels of vitamin A
These are described as generally temporary. A doctor should be consulted if they persist, and any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- A complete medical history should be shared with the doctor before starting treatment
- All current medicines and supplements should be disclosed to the doctor
- Its labelling describes a reduction in serum vitamin A; any eye or vision symptoms should be reported to the doctor for assessment
- Pregnancy or breastfeeding should be discussed with the doctor before treatment
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains eplontersen and is described for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as a subcutaneous injection given by a doctor or nurse on the schedule set by the treating specialist. Supplementation with the recommended daily allowance of vitamin A is described during treatment.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.